A study conducted at the University of São Paulo (USP) in Brazil shows that brilacidin, a new drug tested for treatment of diseases ranging from bacterial skin infections to COVID-19, can kill drug-resistant strains of fungi when combined with two classes of antifungals available on the market.
AC Immune’s Alzheimer’s drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M
AC Immune’s anti-pTau drug enters PhIIb: The Swiss biotech’s partner Johnson & Johnson launched the “potentially registration-enabling” study of ACI-35.030 in people with preclinical Alzheimer’s
December 16, 2023